Found 12 matching trials
Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology
N/AThe main aim of this study is to observe correction of the hemoglobin level...
Location
Multiple Locations
Study of Haemodialysis Patients Switching From Aranesp to Biosimilar
N/AThe study will obtain data to show insight into clinical outcomes of patien...
Biosimilar Erythropoietin in Anaemia Treatment (Correction Phase Study)
PHASE4This study is aimed to comprehensively establish the biosimilarity/bioquiva...
Location
Bamrasnaradura Infectious Disease Institute
Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
N/AThe purpose of this study is to observe correction of haemoglobin (Hb) leve...
Location
Multiple Locations
Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study)
PHASE3This study is aimed to comprehensively establish the bio-similarity/bioequi...
Location
State Budgetary Healthcare Institution "Volgogradskiy Regional Center of Urology and Nephrology"
Efficacy Study of Two Formulations of Erythropoietin
PHASE3A double-blind, randomized trial aimed to compare the efficacy of two formu...
Location
Multiple Locations
Evaluation of Response to Biosimilar Erythropoietin Alfa Therapy in Anemic Patients With Myelodysplastic Syndrome
N/AThe primary objective of this study is to describe the response to treatmen...
Location
IRCCS Azienda Ospedaliera -Universitaria di Bologna
A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis
PHASE2This is a phase II study to evaluate the safety and efficacy of AND017 in r...
Location
US Renal Care - Pine Bluff
Effectiveness of a Biosimilar Epoetin Alfa in Stable 'End Stage Renal Failure'
N/AThis is a prospective, observational, non-inferior study in ESRF patients s...
Location
Multiple Locations
Hydroxyurea and EPO in Sickle Cell Disease
PHASE1The proposed study is a Phase 1/2 multi-center study evaluating the safety ...